

# Françoise Kraeber-Bodéré

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4031867/publications.pdf>

Version: 2024-02-01

192  
papers

5,947  
citations

66343

42  
h-index

95266

68  
g-index

212  
all docs

212  
docs citations

212  
times ranked

6277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6077-6084.	3.6	361
2	Prospective Evaluation of Magnetic Resonance Imaging and [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	1.6	247
3	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti <sup>125</sup> I-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	1.6	231
4	Does <sup>18</sup> F-FDG PET/CT Improve the Detection of Posttreatment Recurrence of Head and Neck Squamous Cell Carcinoma in Patients Negative for Disease on Clinical Follow-up?. <i>Journal of Nuclear Medicine</i> , 2009, 50, 24-29.	5.0	231
5	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1393-1406.	6.4	199
6	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4806-4819.	7.0	136
7	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. <i>Haematologica</i> , 2008, 93, 471-472.	3.5	130
8	Analysis of <sup>18</sup> F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1813-1821.	6.4	111
9	Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1487-1493.	2.1	107
10	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	1.6	106
11	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597.	3.6	89
12	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and <sup>131</sup> I-labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	5.0	88
13	Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50.	6.4	85
14	Standardization of <sup>18</sup> F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	1.6	85
15	High Frequency of Bone/Bone Marrow Involvement in Advanced Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 779-788.	3.6	79
16	<sup>18</sup> F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1669-1678.	6.4	77
17	Prognostic impact of <sup>18</sup> F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	6.4	76
18	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	5.0	74

#	ARTICLE	IF	CITATIONS
19	Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Research, 2013, 3, 11.	2.5	67
20	Pretargeting with the Affinity Enhancement System for Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 153-166.	1.0	65
21	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 4794-4805.	7.0	65
22	<sup>213</sup> Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. Journal of Nuclear Medicine, 2013, 54, 1597-1604.	5.0	65
23	Radioimmunoconjugates for the Treatment of Cancer. Seminars in Oncology, 2014, 41, 613-622.	2.2	65
24	Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery, 2007, 142, 952-958.	1.9	63
25	Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. Journal of Nuclear Medicine, 2003, 44, 2000-18.	5.0	62
26	Radiolabeled Antibodies for Cancer Imaging and Therapy. Methods in Molecular Biology, 2012, 907, 681-697.	0.9	61
27	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and <sup>68</sup> Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. Journal of Nuclear Medicine, 2016, 57, 1505-1511.	5.0	61
28	Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials. PLoS ONE, 2016, 11, e0159984.	2.5	61
29	Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer, 2002, 94, 1202-1209.	4.1	60
30	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> “RAF” Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	7.0	60
31	Fractionated <sup>90</sup> Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to CELF/BNLI Criteria. Journal of Clinical Oncology, 2014, 32, 212-218.	1.6	57
32	Cell Tracking in Cancer Immunotherapy. Frontiers in Medicine, 2020, 7, 34.	2.6	52
33	Does <sup>18</sup> F-fluoro- <sup>18</sup> F-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?. Head and Neck, 2007, 29, 1115-1120.	2.0	51
34	FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1029-1036.	6.4	51
35	Tumor Immunotargeting Using Innovative Radionuclides. International Journal of Molecular Sciences, 2015, 16, 3932-3954.	4.1	51
36	Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, 2017, 18, 57.	4.1	50

#	ARTICLE	IF	CITATIONS
37	Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. <i>Tumor Biology</i> , 2012, 33, 679-688.	1.8	48
38	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	1.4	48
39	Feasibility and benefit of fluorine 18â€“fluoro-2-deoxyglucoseâ€“guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. <i>Surgery</i> , 2005, 138, 1176-1182.	1.9	45
40	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	3.5	45
41	99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 637-643.	6.4	44
42	Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. <i>EJNMMI Research</i> , 2011, 1, 20.	2.5	44
43	<sup>18</sup> F-fluorodeoxyglucose positron emission tomographyâ€“computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study. <i>International Journal of Urology</i> , 2013, 20, 788-796.	1.0	43
44	Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. <i>Cancers</i> , 2019, 11, 1282.	3.7	43
45	Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1270-1278.	6.4	42
46	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692.	1.4	42
47	Nuclear Medicine Applications for Neuroendocrine Tumors. <i>World Journal of Surgery</i> , 2000, 24, 1285-1289.	1.6	41
48	A pretargeting system for tumor PET imaging and radioimmunotherapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 54.	3.5	41
49	Pretargeting for imaging and therapy in oncological nuclear medicine. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 6.	3.9	41
50	Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. <i>Clinical Cancer Research</i> , 2003, 9, 3973S-81S.	7.0	37
51	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e108-e117.	4.6	36
52	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	6.4	35
53	Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , 2019, 6, 69.	2.6	34
54	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. <i>Cancer</i> , 2010, 116, 1093-1100.	4.1	33

#	ARTICLE	IF	CITATIONS
55	Consolidation anti-CD22 fractionated radioimmunotherapy with <sup>90</sup> Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
56	Prognostic value of metabolic parameters and clinical impact of <sup>18</sup> F-fluorocholine PET/CT in biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1784-1793.	6.4	32
57	Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146.	4.6	31
58	Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 772.	3.5	31
59	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	3.5	31
60	Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 267-74.	4.1	31
61	Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. <i>Frontiers in Oncology</i> , 2013, 3, 177.	2.8	30
62	Improvement of Radioimmunotherapy Using Pretargeting. <i>Frontiers in Oncology</i> , 2013, 3, 159.	2.8	30
63	<sup>18</sup> F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 131-137.	2.4	30
64	Quality of Life is Modestly Improved in Older Patients with Mild Primary Hyperparathyroidism Postoperatively: Results of a Prospective Multicenter Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 3534-3540.	1.5	30
65	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84.	2.6	29
66	Comparison of Immuno-PET of CD138 and PET imaging with <sup>64</sup> CuCl <sub>2</sub> and <sup>18</sup> F-FDG in a preclinical syngeneic model of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 9061-9072.	1.8	29
67	<sup>18</sup> F-FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2008, 93, 128-131.	3.5	28
68	Prospective comparison of two gamma probes for intraoperative detection of <sup>18</sup> F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1556-1562.	6.4	27
69	Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 275-281.	1.6	27
70	Radioimmunoconjugates for treating cancer: recent advances and current opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 813-819.	3.1	27
71	Current Status and Perspectives in Peptide Receptor Radiation Therapy. <i>Current Pharmaceutical Design</i> , 2009, 15, 2453-2462.	1.9	26
72	Laparoscopic Sentinel Lymph Node Versus Hyperextensive Pelvic Dissection for Staging Clinically Localized Prostate Carcinoma: A Prospective Study of 200 Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 753-758.	5.0	26

#	ARTICLE	IF	CITATIONS
73	Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. <i>Cancer</i> , 2010, 116, 1053-1058.	4.1	25
74	Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR. <i>Physics in Medicine and Biology</i> , 2014, 59, 6417-6430.	3.0	25
75	Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making. <i>Prostate</i> , 2019, 79, 1514-1522.	2.3	25
76	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. <i>Bone Marrow Transplantation</i> , 2011, 46, 393-399.	2.4	24
77	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of $\hat{\rho}$ SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , 2018, 24, 5219-5224.	7.0	24
78	ImmunoPET to help stratify patients for targeted therapies and to improve drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2166-2168.	6.4	23
79	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 445.	4.1	23
80	Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 431-438.	1.9	23
81	Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by <sup>18</sup> F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1836-1846.	5.0	22
82	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between <sup>89</sup> Zr- and <sup>64</sup> Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2564.	4.1	22
83	Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 129-139.	2.8	22
84	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1205-1211.	5.0	22
85	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. <i>PLoS ONE</i> , 2017, 12, e0183841.	2.5	22
86	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	1.3	21
87	XEMIS: A liquid xenon detector for medical imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2015, 787, 89-93.	1.6	20
88	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	2.6	20
89	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	1.4	20
90	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. <i>Cancer</i> , 2010, 116, 1118-1125.	4.1	19

#	ARTICLE	IF	CITATIONS
91	Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. <i>Journal of Nuclear Medicine</i> , 2010, 51, 624-631.	5.0	19
92	Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 291-299.	6.4	19
93	<sup>131</sup> I-BCR-ABL1 molecular remission after <sup>90</sup> Y- <sup>125</sup> I-pratuzumab tetraxetan radioimmunotherapy in <sup>18</sup> F-CD22- <sup>125</sup> I-P <sup>125</sup> h <sup>125</sup> : proof of principle. <i>European Journal of Haematology</i> , 2013, 91, 552-556.	2.2	19
94	Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1559-1574.	6.4	19
95	Intra-arterial injection of <sup>131</sup> I-labeled Lipiodol for advanced hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2013, 34, 674-681.	1.1	18
96	Prognostic Value and Clinical Impact of <sup>18</sup> F-FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. <i>Frontiers in Medicine</i> , 2014, 1, 54.	2.6	17
97	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , 2020, 12, 2532.	3.7	17
98	<i>Review:</i> What Can Be Expected from Nuclear Medicine Tomorrow?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 483-504.	1.0	16
99	Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. <i>Frontiers in Medicine</i> , 2015, 2, 46.	2.6	16
100	Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 313-318.	1.9	15
101	Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 329-331.	5.0	15
102	<sup>18</sup> F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1380-1385.	5.0	15
103	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). <i>Tumor Biology</i> , 2012, 33, 601-606.	1.8	14
104	<sup>18</sup> F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	6.4	14
105	<sup>68</sup> Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive <sup>18</sup> F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. <i>Prostate</i> , 2019, 79, 454-461.	2.3	14
106	Variation in phytoplankton composition and limnological features in a water-water ecotone of the Lower Paraná Basin (Argentina). <i>Freshwater Biology</i> , 2001, 46, 63-74.	2.4	13
107	Interest of FDG-PET in the Management of Mantle Cell Lymphoma. <i>Frontiers in Medicine</i> , 2019, 6, 70.	2.6	13
108	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5406.	4.1	13

#	ARTICLE	IF	CITATIONS
109	Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. <i>Cancers</i> , 2020, 12, 2424.	3.7	13
110	Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors. <i>Oncotarget</i> , 2017, 8, 77050-77060.	1.8	13
111	XEMIS2: A liquid xenon detector for small animal medical imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2018, 912, 329-332.	1.6	12
112	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1221-1227.	5.0	12
113	Sensitivity of pretargeted immunoPET using <sup>68</sup> Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with <sup>18</sup> F-FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	1.8	12
114	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 222-225.	1.3	11
115	Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. <i>Cancers</i> , 2020, 12, 2721.	3.7	11
116	Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine. <i>Frontiers in Medicine</i> , 2014, 1, 16.	2.6	10
117	Sodium <sup>18</sup> F-sodium fluoride PET failed to predict responses to TNF $\alpha$ antagonist therapy in 31 patients with possible spondyloarthritis not meeting ASAS criteria. <i>Joint Bone Spine</i> , 2015, 82, 411-416.	1.6	10
118	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with <sup>90</sup> Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. <i>Blood</i> , 2010, 116, 2875-2875.	1.4	10
119	Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. <i>Current Oncology</i> , 2009, 16, 3-8.	2.2	10
120	A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. <i>Gynecologic Oncology</i> , 2007, 105, 545-547.	1.4	9
121	[ <sup>18</sup> F]-Fludarabine for Hematological Malignancies. <i>Frontiers in Medicine</i> , 2019, 6, 77.	2.6	9
122	Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1236-1239.	6.4	8
123	Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time. <i>Journal of Clinical Oncology</i> , 2012, 30, 2165-2165.	1.6	8
124	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. <i>Biomedicines</i> , 2020, 8, 548.	3.2	8
125	ImmunoPET in Multiple Myeloma – What? So What? Now What?. <i>Cancers</i> , 2020, 12, 1467.	3.7	8
126	Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Cancers</i> , 2020, 12, 486.	3.7	8



#	ARTICLE	IF	CITATIONS
127	$^{137}\text{Cs}$ Medical Imaging with a Liquid Xenon Compton Camera and $^{125}\text{I}$ Radionuclide. Acta Physica Polonica B, 2017, 48, 1661.	0.8	8
128	Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y. Journal of Clinical Oncology, 2008, 26, 8502-8502.	1.6	7
129	Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor.. Journal of Clinical Oncology, 2011, 29, 3017-3017.	1.6	7
130	Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1373-1376.	6.4	6
131	Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with $^{18}\text{F}$ -Choline PET/CT in Prostate Cancer. Frontiers in Medicine, 2015, 2, 67.	2.6	6
132	Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology, 2016, 107, 182-189.	4.4	6
133	Isolation of Coxiella burnetii from an acromioclavicular infection with low serological titres. International Journal of Infectious Diseases, 2018, 73, 27-29.	3.3	6
134	Gravity assisted recovery of liquid xenon at large mass flow rates. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2018, 893, 10-14.	1.6	6
135	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 906-911.	2.0	6
136	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. Cancers, 2020, 12, 1384.	3.7	6
137	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. Blood, 2015, 126, 335-335.	1.4	6
138	Évaluation de la réponse thérapeutique par tomographie par Émission de positons (TEP) au $^{18}\text{F}$ -fluoro-désoxyglucose (FDG) en oncologie-hématologie. Médecine Nucleaire, 2011, 35, 600-607.	0.2	5
139	$^{18}\text{F}$ -FDOPA PET Compared With $^{123}\text{I}$ -Metaiodobenzylguanidine Scintigraphy and $^{18}\text{F}$ -FDG PET in Secreting Sporadic Pheochromocytoma. Clinical Nuclear Medicine, 2019, 44, 738-740.	1.3	5
140	Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice. Frontiers in Oncology, 2021, 11, 714514.	2.8	5
141	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with $^{90}\text{Y}$ -Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906.	1.4	5
142	First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2011, 29, 3006-3006.	1.6	5
143	Assessment of a fully 3D Monte Carlo reconstruction method for preclinical PET with iodine-124. Physics in Medicine and Biology, 2015, 60, 2475-2491.	3.0	4
144	Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer. Cancers, 2020, 12, 1512.	3.7	4

#	ARTICLE	IF	CITATIONS
145	Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. <i>Immunotherapy</i> , 2013, 5, 1283-1286.	2.0	3
146	Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 54-65.	0.3	3
147	Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1849-1856.	6.4	3
148	Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology. <i>Frontiers in Medicine</i> , 2016, 3, 74.	2.6	3
149	XEMIS2: A liquid xenon Compton camera to image small animals. , 2019, , .		3
150	Radioimmunotherapy of Lymphomas. , 2019, , 113-121.		3
151	68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level. <i>Clinical Nuclear Medicine</i> , 2019, 44, 40-41.	1.3	3
152	Apport de la TEP/TDM au 18FDG dans la stadification initiale et lâ€™Ä©valuation prÄ©coce de la rÄ©ponse thÄ©rapeutique des rhabdomyosarcomes pÄ©diatriques. <i>Medecine Nucleaire</i> , 2010, 34, 655-663.	0.2	2
153	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. <i>EJHaem</i> , 2020, 1, 318-322.	1.0	2
154	Editorial: Nuclear Medicine in the Context of Personalized Medicine. <i>Frontiers in Medicine</i> , 2020, 7, 252.	2.6	2
155	Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. <i>European Thyroid Journal</i> , 2021, 10, 1-6.	2.4	2
156	La radio-immunothÄ©rapie en clinique. <i>Medecine Nucleaire</i> , 2008, 32, 254-257.	0.2	1
157	Les essais cliniques en mÄ©decine nuclÄ©aire: Ä©tat et perspectives. <i>Medecine Nucleaire</i> , 2009, 33, 296-304.	0.2	1
158	LÄ€™immuno-TEP, une nouvelle approche dÄ©imagerie molÄ©culaire. <i>Medecine Nucleaire</i> , 2010, 34, 295-298.	0.2	1
159	RadiothÄ©rapie vectorisÄ©e: les nouvelles molÄ©cules. <i>Medecine Nucleaire</i> , 2011, 35, 613-616.	0.2	1
160	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. <i>Medical Radiology</i> , 2012, , 551-556.	0.1	1
161	Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. <i>Journal of Nuclear Medicine</i> , 2018, 59, 714-715.	5.0	1
162	Alphatherapy, the new impetus to targeted radionuclide therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1362-1363.	6.4	1

#	ARTICLE	IF	CITATIONS
163	Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153.	0.1	1
164	18F-FDG PET/CT in multiple myeloma: critical insights and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1048-1050.	6.4	1
165	Abstract P5-01-01: Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and a68Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results. , 2015, , .		1
166	Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3889-3889.	1.4	1
167	La place de l'aTTEP auFDG dans l'valuation des lymphomes. Hematologie, 2009, 15, 305-312.	0.0	0
168	La radio-immunothrapie. Medecine Nucleaire, 2009, 33, 148-151.	0.2	0
169	Intt de la tomographie par mission de positons (TEP) au 18FDG dans le suivi des patients traits pour carcinome pidermo de des voies arodigestives suprieures (VADS) en mission clinique. Medecine Nucleaire, 2009, 33, 193-200.	0.2	0
170	%tude de faisabilit du ganglion sentinelle dans le cancer de la prostate par c"lioscopie: premiers rsultats. Medecine Nucleaire, 2011, 35, 461-469.	0.2	0
171	Consolidation par 90Y-epratuzumab en fractionn dans le lymphome B diffus grandes cellules: rsultats praliminaires d'une tude de phase II. Medecine Nucleaire, 2011, 35, 478-486.	0.2	0
172	Intt des traceurs de l'hyponie en radiothrapie. Medecine Nucleaire, 2011, 35, 621-624.	0.2	0
173	Medullary Thyroid Carcinoma. Medical Radiology, 2012, , 315-321.	0.1	0
174	Modlisation du taux de comptage en TEP partir de donn es cliniques: une voie robuste pour l'optimisation des param tres d'acquisition?. Medecine Nucleaire, 2012, 36, 209-214.	0.2	0
175	Les outils de mdecine nuclaire pour le dveloppement de la mdecine personnalis e dans le cancer du sein. Medecine Nucleaire, 2012, 36, 233-236.	0.2	0
176	Les cancers gyncologiques: une prise en charge multidisciplinaire propos de trois cas cliniques. Medecine Nucleaire, 2012, 36, 462-468.	0.2	0
177	Imagerie TEP/TDM FDG du pelvis de la femme. Medecine Nucleaire, 2012, 36, 445-450.	0.2	0
178	Medullary Thyroid Carcinoma. , 2013, , 155-163.		0
179	La place de la TEP au FDG dans l'valuation des lymphomes en 2012. Diagnostic and Interventional Imaging, 2013, 94, 164-174.	0.0	0
180	La TEP au FDG dans l'valuation du mylome en 2012. Diagnostic and Interventional Imaging, 2013, 94, 190-195.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Clinical NECR in 18F-FDG PET scans: Optimization of patient specific activity and variable acquisition time. Relationship with SNR. , 2013, , .		0
182	Impact of Functional and/or Phenotypic PET Imaging on the Determination of Clinical Target Volumes of Vertebral Metastases Before Stereotactic Body Radiation Therapy Compared to MRI. International Journal of Radiation Oncology Biology Physics, 2015, 93, S82-S83.	0.8	0
183	EP-1936 PET/CT Radiomics predict local recurrence in patients treated with SBRT for early-stage NSCLC. Radiotherapy and Oncology, 2019, 133, S1054.	0.6	0
184	Recommandations et rÄ©fÄ©rentiels. Medecine Nucleaire, 2019, 43, 1-4.	0.2	0
185	IntÄ©rÄ©t pronostique et prÄ©dictif de la TEP-TDM au 18F-FDG au bilan initial des mÄ©lanomes de stade IIIB-C-D et IV avant traitement par anti-PD-1. Medecine Nucleaire, 2020, 44, 65-71.	0.2	0
186	Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of RichterÄ©™s Syndrome.. Blood, 2007, 110, 1390-1390.	1.4	0
187	Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immuno-PET targeting CEA: First clinical results.. Journal of Clinical Oncology, 2015, 33, 11059-11059.	1.6	0
188	Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075. Blood, 2015, 126, 3920-3920.	1.4	0
189	Reply to E. Laffon <i>et al</i>.. Haematologica, 2020, 105, e42-e42.	3.5	0
190	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. Blood, 2020, 136, 26-26.	1.4	0
191	Radionuclide Metabolic Therapy. , 2013, , .		0
192	Pilot study with [ <sup>18</sup> F]DPA-714 PET-CT to explore tumor-associated-macrophages in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12557-e12557.	1.6	0